10.18.16
Dr. John Ford has been appointed chief executive officer of Enterprise Therapeutics. The company is developing novel muco-regulatory therapies for Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and severe asthma.
Dr. Ford has more than 18 years of ion channel research, Drug Discovery and development experience. He is a Biotechnology entrepreneur who co-founded Xention, Ario Pharma and Metrion Biosciences. Recently, he was a member of the executive team at Dezima, which developed TA-8995 for dyslipidaemia. Dezima was sold to Amgen in 2015 for as much as $1.6 billion.
Dr. Peter Finan, chairman Enterprise Therapeutics , said, “John’s experience in ion channels, drug development, and biotech fundraising, position him uniquely to Lead Enterprise Therapeutics moving forward. His expertise will complement the existing team and we are thrilled to have him on board.”
Dr. Ford has more than 18 years of ion channel research, Drug Discovery and development experience. He is a Biotechnology entrepreneur who co-founded Xention, Ario Pharma and Metrion Biosciences. Recently, he was a member of the executive team at Dezima, which developed TA-8995 for dyslipidaemia. Dezima was sold to Amgen in 2015 for as much as $1.6 billion.
Dr. Peter Finan, chairman Enterprise Therapeutics , said, “John’s experience in ion channels, drug development, and biotech fundraising, position him uniquely to Lead Enterprise Therapeutics moving forward. His expertise will complement the existing team and we are thrilled to have him on board.”
